Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1388.656
- +15.643+1.14%
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Citi: Maintains Intellia Therapeutics (NTLA.US) rating, adjusted from neutral to neutral, and adjusted the target price from $31.00 to $29.00.
Intellia Therapeutics Analyst Ratings
Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29
Oppenheimer: The CRISPR Therapeutics (CRSP.US) rating was maintained, and the target price was adjusted from superior to superior market rating, and the target price was adjusted from $102.00 to $95.00.
CRISPR Therapeutics Analyst Ratings
Bank of Montreal, Canada: Maintaining the Intellia Therapeutics (NTLA.US) rating, adjusted from superior to superior market rating, target price adjusted from $62.00 to $70.00.
Intellia Therapeutics Analyst Ratings
BMO Capital Maintains Outperform on Intellia Therapeutics, Raises Price Target to $70
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating
Intellia Therapeutics: A Promising Buy Rating Supported by Trial Success and Strong Financials
Analysts' Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
Analysts' Top Healthcare Picks: Caribou Biosciences (CRBU), Lineage Therap (LCTX)
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
William Blair Sticks to Its Hold Rating for Bluebird Bio (BLUE)